Method for purification of monoclonal antibodies
Disclosed is a method for purification of monoclonal antibodies or of a fusion protein between the Fc segment of an antibody and a second polypeptide, including a) an affinity chromatography step on a resin having as a matrix a crosslinked methacrylate polymer gel, on which the protein A is grafted, b) a viral inactivation step, c) a chromatography step exchanging cations on a resin having a crosslinked agarose gel matrix, on which sulfonate groups (—SO 3 —) are grafted using dextran-based spacer arms, d) a chromatography step exchanging anions on a hydrophilic membrane of polyethersulfone coated with a crosslinked polymer on which quaternary amine groups (Q) are grafted, and e) a nanofiltration step using a filter having an asymmetric polyethersulfone double membrane with a porosity of approximately 20 nm.
1. A method for purification of a monoclonal antibody or a fusion protein comprising a Fc fragment of an antibody and a second polypeptide from a sample, comprising:
a) applying said sample comprising the monoclonal antibody or fusion protein to an affinity chromatography resin having as matrix a cross-linked methacrylate polymer gel, on which protein A is grafted, followed by eluting said monoclonal antibody or fusion protein with an elution buffer thereby obtaining a monoclonal antibody or fusion protein composition,
b) inactivating viruses in the composition obtained from step a),
c) applying the composition obtained from step b) to a cation-exchange chromatography resin having as matrix a cross-linked agarose gel, on which sulfonate groups (—SO 3 —) are grafted via dextran-based spacer arms,
d) subjecting the composition obtained from step c) to an anion-exchange chromatography step by applying said composition to a hydrophilic polyethersulfone membrane coated with a cross-linked polymer on which quaternary amine groups (Q) are grafted, and
e) nanofiltering the composition obtained from step d) by applying said composition to a filter having a dual polyethersulfone membrane having a pore size of about 20 nm.
2. The method according to claim 1 , wherein the cross-linked methacrylate polymer gel on which protein A is grafted used in step a) is in the form of beads having an average diameter of between 30 and 60 μm.
3. The method according to claim 1 , wherein step a) comprises a sub-step of washing the resin with a saline solution comprising an NaCl concentration of at least 1 M.
4. The method according to claim 1 , wherein the elution buffer used in step a) to elute the antibody is a formate buffer.
5. The method according to claim 4 , wherein the formate buffer used for the elution of the antibody in step a) is used at a molarity of 5 to 10 mM and at a pH of between 2.6 and 3.6.
6. The method according to claim 1 , wherein step b) is carried out by incubation for 30 to 120 minutes at a temperature of 20 to 25° C. in a medium comprising 0.5 to 2% (v/v) of polyoxyethylene-p-t-octylphenol (CAS no. 9002-93-1).
7. The method according to claim 1 , wherein the membrane used during step d) is equilibrated with a trishydroxymethylaminomethane (TRIS) buffer at a concentration of 15 to 25 mM, a pH of 7.5 to 8.5 and a conductivity of 5 to 15 mS/cm.
8. The method according to claim 1 , wherein step e) further comprises preliminary filtration through a depth filter comprising cellulose fibers, diatomaceous earth and a negatively-charged resin or a polyethersulfone membrane having a pore size of 0.22 μm functionalized by SO 3 − groups.
9. The method according to claim 1 , further comprising an ultrafiltration and/or diafiltration step.
10. The method according to claim 1 , wherein the method is implemented on a culture supernatant of a clone producing the monoclonal antibody or the fusion protein comprising a Fc fragment of an antibody and a second polypeptide.
11. The method according to claim 1 , for the purification of a monoclonal antibody.
12. The method according to claim 11 , wherein the antibody is directed against one of the following antigens: Rhesus D, CD2, CD3, CD4, CD19, CD20, CD22, CD25, CD30, CD33, CD40, CD51 (Integrin alpha-V), CD52, CD80, CTLA-4 (CD152), SLAMF7 (CD319), Her2/neu, EGFR, EPCAM, CCR4, CEA, FR-alpha, GD2, GD3, HLA-DR, IGF1R (CD221), phosphatidylserine, TRAIL-R1, TRAIL-R2, Clostridium difficile antigens, Staphylococcus aureus antigens, cytomegalovirus antigens, Escherichia coli antigens, respiratory syncytial virus antigens, hepatitis B virus antigens, influenza virus A antigens, Pseudomonas aeruginosa serotype IATS O11 antigens, rabies virus antigens, or phosphatidylserine.
13. The method according to claim 2 , wherein said beads have an average diameter of between 40 and 50 μm.